Research ExplorerPublicationsRelative efficacy of treatment options in transplant-ineligi...

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma

Standard

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma : results from a systematic literature review and network meta-analysis. / Ramasamy, Karthik; Dhanasiri, Sujith; Thom, Howard; Buchanan, Vanessa; Robinson, Suzanne; D'Souza, Vijay K; Weisel, Katja.

In: LEUKEMIA LYMPHOMA, Vol. 61, No. 3, 03.2020, p. 668-679.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ramasamy, K, Dhanasiri, S, Thom, H, Buchanan, V, Robinson, S, D'Souza, VK & Weisel, K 2020, 'Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis', LEUKEMIA LYMPHOMA, vol. 61, no. 3, pp. 668-679. https://doi.org/10.1080/10428194.2019.1683736

APA

Ramasamy, K., Dhanasiri, S., Thom, H., Buchanan, V., Robinson, S., D'Souza, V. K., & Weisel, K. (2020). Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. LEUKEMIA LYMPHOMA, 61(3), 668-679. https://doi.org/10.1080/10428194.2019.1683736

Vancouver

Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK et al. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. LEUKEMIA LYMPHOMA. 2020 Mar;61(3):668-679. https://doi.org/10.1080/10428194.2019.1683736

Bibtex

@article{57fe6619e1dc452795fa4a0220dfa2ed,
title = "Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis",
abstract = "Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMP + D), daratumumab plus lenalidomide and dexamethasone (D + Rd). Relative efficacy of these treatments was compared using a network meta-analysis. Eight trials identified by a systematic literature review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for OS and PFS. There was strong evidence that, compared with Rd, both D + Rd and RVd improved PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively). However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).",
author = "Karthik Ramasamy and Sujith Dhanasiri and Howard Thom and Vanessa Buchanan and Suzanne Robinson and D'Souza, {Vijay K} and Katja Weisel",
year = "2020",
month = mar,
doi = "10.1080/10428194.2019.1683736",
language = "English",
volume = "61",
pages = "668--679",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma

T2 - results from a systematic literature review and network meta-analysis

AU - Ramasamy, Karthik

AU - Dhanasiri, Sujith

AU - Thom, Howard

AU - Buchanan, Vanessa

AU - Robinson, Suzanne

AU - D'Souza, Vijay K

AU - Weisel, Katja

PY - 2020/3

Y1 - 2020/3

N2 - Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMP + D), daratumumab plus lenalidomide and dexamethasone (D + Rd). Relative efficacy of these treatments was compared using a network meta-analysis. Eight trials identified by a systematic literature review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for OS and PFS. There was strong evidence that, compared with Rd, both D + Rd and RVd improved PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively). However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).

AB - Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMP + D), daratumumab plus lenalidomide and dexamethasone (D + Rd). Relative efficacy of these treatments was compared using a network meta-analysis. Eight trials identified by a systematic literature review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for OS and PFS. There was strong evidence that, compared with Rd, both D + Rd and RVd improved PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively). However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).

U2 - 10.1080/10428194.2019.1683736

DO - 10.1080/10428194.2019.1683736

M3 - SCORING: Journal article

C2 - 31709875

VL - 61

SP - 668

EP - 679

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 3

ER -